BOS-318 treatment enhances elexacaftor–tezacaftor–ivacaftor-mediated improvements in airway hydration and mucociliary transport
Background Cystic fibrosis transmembrane conductance regulator (CFTR) triple modulator therapy, elexacaftor–tezacaftor–ivacaftor (ETI) has transformed care for people with cystic fibrosis (CF) who have eligible mutations. It is, however, not curative. Response to treatment also varies and lung disea...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2025-02-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/11/1/00445-2024.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|